Otsuka Pharmaceutical and its US subsidiary Otsuka Pharmaceutical Development & Commercialization said on December 19 that they have launched a global PIII trial of repinatrabit (JNT-517) for phenylketonuria (PKU). The study will enroll 120 patients with PKU, who will receive…
To read the full story
Related Article
- Otsuka Wraps Up Buyout of Jnana Therapeutics
September 25, 2024
- Otsuka Wants to Make Jnana Cornerstone of Future Drug Discovery: CEO
August 5, 2024
- Otsuka Picks Up Jnana Therapeutics for US$800 Million
August 2, 2024
BUSINESS
- Rhythm Pharma Gears Up for First Japan Launch with 50-Strong Team
July 21, 2026
- Fujifilm Toyama Chemical Forms 1st Product-Dedicated Unit for Savyscus
July 21, 2026
- Meiji’s Hiyasta Earns Approval in Thailand
July 21, 2026
- US FDA Accepts Shionogi’s Pediatric Fetroja Filing
July 21, 2026
- Kaken’s Vascular Malformation Drug Shows Efficacy in Japan PIII
July 21, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





